Guardians at the gate: patent protection for therapeutic monoclonal antibodies--part 1.
Patents provide one of the few protections companies can avail themselves of to help protect their therapeutic monoclonal antibody products. Just as the therapeutic monoclonal antibody field is constantly evolving, so too is the legal environment surrounding these inventions. In a series of articles, the general state of the law surrounding therapeutic antibodies will be explained, and important challenges to this technology area will be discussed. Much is at stake when companies market therapeutic monoclonal antibodies; therefore, a firm understanding of this important form of protection is critically important for anyone developing such products.
McCabe
Kevin W
KW
Sterne, Kessler, Goldstein & Fox P.L.L.C., Washington DC 20005, USA. kmccabe@skgf.com
D000911:Antibodies, Monoclonal / Q000096:biosynthesis* / Q000627:therapeutic use*; D006801:Humans; D010067:Ownership; D010330:Patents as Topic / Q000331:legislation & jurisprudence*
D000911:Antibodies, Monoclonal